Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06226363 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase I Study of LNF1901 in Advanced Malignant Tumors

StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 26, 2024 (before its estimated February 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This is a multicenter, open, phase I dose-escalation and dose-expansion study to evaluate the safety, tolerability, initial antitumor efficacy, PK and immunogenic characteristics of LNF1901 in patients with advanced malignancies.
Trial Details
NCT Number NCT06226363
Lead Sponsor Shandong New Time Pharmaceutical Co., LTD
Collaborators: Sun Yat-sen University
Conditions
(from sponsor)		 Advanced Malignant Tumors
Enrollment 82 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov